ANTS Trial (Australian Neoadjuvant Therapy Study for Non-small Cell Lung Cancer)
- Conditions
- on-small Cell Lung Cancer (NSCLC)Non-small Cell Lung Cancer (NSCLC)Cancer - Lung - Non small cell
- Registration Number
- ACTRN12608000061336
- Lead Sponsor
- Austin Health
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 100
1) Histological diagnosis of NSCLC
2) Adequate baseline histological specimen available
3) Measurable primary tumour
4) Stage II or IIIA
5) Considered to be surgically resectable by thoracic surgeon
6) No prior therapy for NSCLC
7) Performance Status 0-1
8) Peripheral neuropathy no worse than grade I
9) Adequate organ function including lung, hepatic, renal and haematological function
10) Written informed consent
1) No prior malignancy within 5 years
2) No other concurrent investigational drug
3) No active infection
4) No pregnancy or breast feeding
5) No serious concomitant medical or psychiatric disorders
6) No significant cardiovascular disease
7) No concurrent systemic corticosteroid (prednisolone >10 mg/day, or equivalent)
8) No history of severe hypersensitivity reactions to polysorbate 80 or any of the study medications.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method